Met all primary endpoints: Vaccine was well-tolerated with robust immunogenicity
Continue to expect topline data from Phase 2 GI.1 challenge study in Q3 2023
https://www.biospace.com/article/releases/vaxart-announces-positive-preliminary-topline-data-from-dose-ranging-phase-2-study-of-its-bivalent-norovirus-vaccine-candidate/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.